Total Anomalous Pulmonary Venous Connection (TAPVC) in India and UAE | Complete Patient Guide

• Confirmed TAPVC of any Darling subtype (I–IV), diagnosed via transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), cardiac CT angiography (CCTA), or cardiac MRI

• Neonates, infants, and young children with obstructed TAPVC presenting as a surgical emergency (emergent indication regardless of weight or gestational maturity)

• Non-obstructed TAPVC patients with progressive cyanosis (SpO2 persistently <85%), right ventricular dilation, or pulmonary-to-systemic flow ratio (Qp:Qs) >1.5:1 detected on cardiac catheterization or Doppler echocardiography

• Infants with failure to thrive, recurrent lower respiratory tract infections, or pulmonary hypertension attributable to TAPVC physiology

• Mixed TAPVC (Type IV) requiring staged or simultaneous multi-level repair, planned in conjunction with a multidisciplinary pediatric cardiac team

Required Diagnostic Workup Prior to Surgical Referral:

• Two-dimensional and color-flow Doppler transthoracic echocardiography (TTE): definitive identification of pulmonary vein drainage anatomy, assessment of venous obstruction gradient (>3 mmHg is clinically significant), right ventricular function, pulmonary artery pressure estimation, and atrial septal defect sizing

• Cardiac CT Angiography (CCTA) with 3D reconstruction: gold standard for delineating the spatial relationship of the pulmonary venous confluence, vertical vein, and systemic venous connections, particularly in complex mixed or infracardiac types

• Cardiac MRI (where infant weight and clinical stability permit): quantification of Qp:Qs ratio, right ventricular volumes, and ventricular function without radiation

• Chest X-ray: classic 'figure-of-8' or 'snowman' silhouette in supracardiac TAPVC; pulmonary venous congestion pattern in obstructed infracardiac TAPVC

• Arterial blood gas (ABG): severity of hypoxemia, metabolic acidosis

• Complete blood count, comprehensive metabolic panel, coagulation studies (PT/aPTT/fibrinogen), and blood type and crossmatch

• Cardiac catheterization with hemodynamic assessment: reserved for complex or mixed cases where echocardiography and CCTA are inconclusive, or to measure precise pulmonary vascular resistance index (PVRI) prior to repair

• Preoperative prostaglandin E1 (PGE1) infusion: indicated in critically obstructed TAPVC to maintain ductal patency and improve systemic perfusion while awaiting emergent surgery

Contraindications and High-Risk Considerations:

• Severe, fixed pulmonary arterial hypertension with pulmonary vascular resistance index (PVRI) >8–10 Wood units·m² unresponsive to vasodilator challenge (relative contraindication; may require medical optimization with sildenafil, iloprost, or inhaled nitric oxide prior to surgery)

• Extreme prematurity (<28 weeks gestational age) or birth weight <1,500 g: increased procedural risk; multidisciplinary consensus required; may require bridging strategies

• Concomitant non-cardiac major congenital anomalies or genetic syndromes with limited survival prognosis

• Active systemic sepsis or uncontrolled coagulopathy not correctable prior to surgery (relative contraindication; emergent repair may still be life-saving in obstructed TAPVC)

• Severe, irreversible end-organ dysfunction (hepatic failure in infracardiac TAPVC with prolonged obstruction)

TAPVC repair is exclusively a surgical procedure; there is no catheter-based or medical definitive treatment. However, the operative approach, adjuncts, and reintervention strategies have evolved substantially.

1. Standard Open Surgical Repair (Primary Approach — All Subtypes)

The foundational technique involves median sternotomy, institution of cardiopulmonary bypass (CPB) using aortic and bicaval cannulation, and cardiac arrest with cold crystalloid or blood cardioplegia. Deep hypothermic circulatory arrest (DHCA) at core temperatures of 18–20°C is employed for neonates and small infants to provide a bloodless operative field, with cerebral perfusion protection strategies (antegrade cerebral perfusion via right axillary artery or direct cannulation of the innominate artery) increasingly used to reduce neurological injury associated with DHCA.

• Supracardiac TAPVC (Type I): The common pulmonary venous confluence is exposed posterior to the heart. A wide side-to-side anastomosis is created between the posterior wall of the left atrium and the anterior wall of the confluence using absorbable suture (polydioxanone or polyglycolic acid) or fine polypropylene. The vertical vein is ligated at its junction with the innominate vein or superior vena cava. The atrial septal defect or patent foramen ovale is closed with a pericardial patch or direct suture.

• Cardiac TAPVC (Type II, coronary sinus type): The roof of the coronary sinus is unroofed and the atrial septal defect is patched so that the coronary sinus opening drains into the left atrium, redirecting all pulmonary venous return to the left side. Care is taken to avoid injury to the atrioventricular node and coronary sinus orifice.

• Infracardiac TAPVC (Type III): This subtype typically presents as an emergency. The common pulmonary venous confluence is mobilized from the descending vertical vein. A generous posterior left atrial anastomosis is constructed, and the descending vertical vein is ligated at the level of the diaphragm. Right atriotomy is performed for ASD closure. The proximity of the descending vein to the esophagus and thoracic duct demands meticulous dissection.

• Mixed TAPVC (Type IV): Requires individualized planning; may involve simultaneous repair of multiple drainage levels or a staged approach. Intraoperative TEE is mandatory to confirm anastomotic adequacy and residual obstruction prior to decannulation.

2. Sutureless (Pericardium-In-Situ) Repair Technique

Originated by Lacour-Gayet and now widely adopted for cases at high risk of postoperative pulmonary venous obstruction (PVO), the sutureless technique avoids suturing directly on pulmonary vein tissue—which is prone to intimal proliferation and restenosis. Instead, the pericardial sac surrounding the pulmonary veins is used as the posterior wall of the anastomosis; the left atrial wall is sutured to the pericardium at a distance from the pulmonary vein ostia, creating a wide, suture-free channel. This approach is now the preferred primary strategy at many high-volume centers for infracardiac TAPVC and for any TAPVC with venous obstruction, due to significantly lower rates of postoperative PVO (2–5% vs. 10–18% with conventional repair) and superior freedom from reoperation at 5 years.

3. Management of Postoperative Pulmonary Venous Obstruction (PVO)

Residual or recurrent PVO following primary repair is the most challenging complication in TAPVC management.

• Surgical revision with sutureless technique: Preferred approach for anatomically accessible obstruction; involves excision of obstructing fibrous tissue and conversion to or repeat sutureless anastomosis.

• Transcatheter interventions: Percutaneous balloon pulmonary venoplasty and drug-eluting stent placement in pulmonary vein ostia are increasingly used as palliative or bridging procedures, particularly in bilateral multi-vessel PVO not amenable to surgical revision. Outcomes with bare-metal stents have been suboptimal due to in-stent restenosis; drug-eluting stents (paclitaxel- or sirolimus-eluting) show early promise.

• Hybrid approach: Combined surgical re-do and intraoperative catheter-based dilation/stenting in a hybrid cardiac catheterization/operating room suite, available at select quaternary centers.

• Antifibrotic pharmacotherapy: Emerging data support adjunctive use of imatinib (a tyrosine kinase inhibitor targeting platelet-derived growth factor receptor, which drives pulmonary vein intimal proliferation) as compassionate-use therapy in refractory PVO. This is not yet standard of care but is practiced at leading centers worldwide.

4. Perioperative Adjuncts

• Inhaled nitric oxide (iNO): Standard therapy for postoperative pulmonary hypertensive crises, weaned gradually over 24–72 hours as pulmonary vascular resistance normalizes.

• Sildenafil (phosphodiesterase-5 inhibitor): Oral or enteral sildenafil is used to facilitate iNO weaning and to manage residual pulmonary hypertension in the postoperative period.

• Milrinone: Phosphodiesterase-3 inhibitor used as inotropic and lusitropic support for left ventricular dysfunction in the early post-bypass period (left ventricle is small and relatively non-compliant after years of low filling volumes).

• High-frequency oscillatory ventilation (HFOV): Reserved for refractory postoperative respiratory failure and pulmonary hypertensive crisis.

• Extracorporeal membrane oxygenation (ECMO): Available at major centers as rescue therapy for postoperative cardiac or respiratory failure unresponsive to maximal medical management.

Phase 1 — Remote Pre-Surgical Evaluation (Weeks 1–2, before travel) Families submit echocardiography reports, cardiac CT or MRI imaging, operative/discharge summaries (if prior intervention), and pediatric cardiology notes to GAF Healthcare's clinical team. A GAF-affiliated pediatric cardiac surgeon and pediatric cardiologist review all records within 48–72 hours and issue a formal surgical opinion, including subtype classification, urgency categorization (elective vs. semi-urgent vs. emergent), estimated procedural complexity, and recommended destination (India or UAE) based on center expertise and family logistics. For obstructed TAPVC presenting acutely, GAF Healthcare coordinates emergency admission directly, bypassing routine elective timelines.

Phase 2 — Pre-Arrival Preparation (Week 2) GAF Healthcare assists with e-Medical Visa application for India (typically approved within 24–72 hours; valid for up to 60 days with two entries) or UAE entry visa facilitation. Flight itineraries are reviewed to ensure the infant is stable for travel; oxygen supplementation during flight is arranged if SpO2 is borderline. The family receives a pre-travel checklist: current medications (including PGE1 infusion documentation if applicable), feeding history, growth chart, allergy list, and vaccination record.

Phase 3 — Hospital Admission and Preoperative Assessment (Days 1–3 in country) Upon arrival, a GAF-assigned patient coordinator meets the family at the airport and transfers them directly to the hospital. Pediatric cardiology admission workup is completed: repeat TTE/TEE, chest X-ray, ABG, full blood count, coagulation screen, metabolic panel, and anesthetic assessment. A pediatric cardiac anesthesiologist meets the family to explain anesthetic technique, DHCA risks, and neuroprotection strategy. The pediatric cardiac surgeon discusses surgical anatomy, operative plan (standard vs. sutureless technique), expected CPB and DHCA duration, and contingency plans. Informed consent is obtained with an interpreter present if required.

Phase 4 — Surgical Procedure (Day 3–5 of admission) Surgery is performed under general anesthesia. Intraoperative TEE is used throughout. Median sternotomy is performed; CPB is established; DHCA (18–20°C) is induced with or without antegrade cerebral perfusion. The specific repair technique (standard or sutureless) is executed as planned. Intraoperative TEE confirms anastomotic patency, absence of residual obstruction, adequate ASD closure, and biventricular function before CPB is separated. The chest is closed; temporary epicardial pacing wires and mediastinal drains are placed. Total operative time ranges from 3 to 6 hours depending on anatomical complexity.

Phase 5 — Pediatric Cardiac Intensive Care Unit (PCICU) (Days 1–7 post-surgery) The infant is admitted to the PCICU intubated and mechanically ventilated. Key management priorities include: inhaled nitric oxide for pulmonary hypertension management, milrinone infusion for left ventricular support, careful fluid balance to avoid left atrial hypertension, and management of chylothorax or pleural effusions if present. Extubation is targeted within 24–48 hours for uncomplicated cases, longer for complex or obstructed subtypes. Daily echocardiography monitors anastomotic flow and pulmonary venous gradients. Sildenafil is initiated enterally prior to iNO weaning. Parents receive daily structured updates and are encouraged toward kangaroo care once the infant is extubated and hemodynamically stable.

Phase 6 — Step-Down Cardiac Ward (Days 7–14 post-surgery) Once hemodynamically stable, the infant is transferred to the cardiac step-down unit. Enteral feeding is advanced; a dietitian optimizes caloric density to support catch-up growth. Oral sildenafil, diuretics (furosemide with spironolactone), and aspirin (low-dose antiplatelet therapy) are prescribed as discharge medications. Predischarge TTE is performed to confirm unobstructed pulmonary venous drainage and ventricular function. Chest physiotherapy is provided; wound care is completed.

Phase 7 — Hospital Discharge and In-Country Recovery (Weeks 3–6 post-surgery) Discharge typically occurs 10–18 days after surgery for uncomplicated cases. GAF Healthcare arranges accommodation near the hospital for the family. A formal post-discharge outpatient echocardiogram is scheduled at 2–3 weeks after discharge to screen for early PVO and evaluate left ventricular remodeling. A final fit-to-fly assessment is conducted by the surgical and cardiology team at 4–6 weeks post-surgery, confirming: SpO2 >95% on room air, stable hemodynamics off inotropes, no active pleural effusion, sternal healing confirmed clinically, and satisfactory echocardiographic result. A comprehensive medical summary, echocardiography report, operative note, and medication plan are provided for the receiving cardiologist at home.

Phase 8 — Long-Term Follow-Up GAF Healthcare provides a structured telemedicine follow-up plan at 3 months, 6 months, and 12 months post-surgery. Families are counseled on warning signs of late PVO (progressive cyanosis, tachypnea, failure to thrive) and advised to schedule annual pediatric cardiology follow-up with echocardiography for a minimum of 5–10 years post-repair.